CGEN
Price
$1.98
Change
+$0.06 (+3.12%)
Updated
Apr 29, 6:59 PM EST
9 days until earnings call
NGNE
Price
$33.40
Change
+$3.44 (+11.48%)
Updated
Apr 29, 6:59 PM EST
Ad is loading...

Compare predictions CGEN vs NGNE

Header iconCGEN vs NGNE Comparison
Open Charts CGEN vs NGNEBanner chart's image
Compugen
Price$1.98
Change+$0.06 (+3.12%)
Volume$166.23K
CapitalizationN/A
Neurogene
Price$33.40
Change+$3.44 (+11.48%)
Volume$49.42K
CapitalizationN/A
View a ticker or compare two or three
CGEN vs NGNE Comparison Chart

Loading...

CGENDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NGNEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CGEN vs. NGNE commentary
Apr 30, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CGEN is a Hold and NGNE is a Hold.

COMPARISON
Comparison
Apr 30, 2024
Stock price -- (CGEN: $1.98 vs. NGNE: $33.40)
Brand notoriety: CGEN and NGNE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CGEN: 53% vs. NGNE: 75%
Market capitalization -- CGEN: $178.76M vs. NGNE: $429.29M
CGEN [@Biotechnology] is valued at $178.76M. NGNE’s [@Biotechnology] market capitalization is $429.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $566.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CGEN’s FA Score shows that 0 FA rating(s) are green whileNGNE’s FA Score has 1 green FA rating(s).

  • CGEN’s FA Score: 0 green, 5 red.
  • NGNE’s FA Score: 1 green, 4 red.
According to our system of comparison, both CGEN and NGNE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CGEN’s TA Score shows that 5 TA indicator(s) are bullish while NGNE’s TA Score has 3 bullish TA indicator(s).

  • CGEN’s TA Score: 5 bullish, 4 bearish.
  • NGNE’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CGEN is a better buy in the short-term than NGNE.

Price Growth

CGEN (@Biotechnology) experienced а +4.76% price change this week, while NGNE (@Biotechnology) price change was +9.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.59%. For the same industry, the average monthly price growth was -6.46%, and the average quarterly price growth was +1250.58%.

Reported Earning Dates

CGEN is expected to report earnings on Aug 05, 2024.

NGNE is expected to report earnings on Nov 14, 2023.

Industries' Descriptions

@Biotechnology (+5.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CGEN with price predictions.
OPEN
A.I.dvisor published
a Summary for NGNE with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
NGNE($429M) has a higher market cap than CGEN($179M). NGNE YTD gains are higher at: 54.592 vs. CGEN (-3.030).
CGENNGNECGEN / NGNE
Capitalization179M429M42%
EBITDAN/AN/A-
Gain YTD-3.03054.592-6%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
CGEN vs NGNE: Fundamental Ratings
CGEN
NGNE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
30
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9599
PRICE GROWTH RATING
1..100
3635
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NGNE's Valuation (30) in the null industry is in the same range as CGEN (37) in the Biotechnology industry. This means that NGNE’s stock grew similarly to CGEN’s over the last 12 months.

NGNE's Profit vs Risk Rating (100) in the null industry is in the same range as CGEN (100) in the Biotechnology industry. This means that NGNE’s stock grew similarly to CGEN’s over the last 12 months.

CGEN's SMR Rating (95) in the Biotechnology industry is in the same range as NGNE (99) in the null industry. This means that CGEN’s stock grew similarly to NGNE’s over the last 12 months.

NGNE's Price Growth Rating (35) in the null industry is in the same range as CGEN (36) in the Biotechnology industry. This means that NGNE’s stock grew similarly to CGEN’s over the last 12 months.

NGNE's P/E Growth Rating (100) in the null industry is in the same range as CGEN (100) in the Biotechnology industry. This means that NGNE’s stock grew similarly to CGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CGENNGNE
RSI
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 5 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 5 days ago
83%
Momentum
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 5 days ago
76%
MACD
ODDS (%)
N/A
Bearish Trend 5 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 5 days ago
85%
Bearish Trend 5 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 5 days ago
86%
Bearish Trend 5 days ago
84%
Advances
ODDS (%)
N/A
Bullish Trend 8 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 6 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
87%
N/A
Aroon
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 5 days ago
87%
View a ticker or compare two or three
Ad is loading...
CGENDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NGNEDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GGRUX11.560.26
+2.30%
Goldman Sachs Strategic Growth R6
ITGSX84.761.64
+1.97%
VY® T. Rowe Price Growth Equity S
ALBAX68.330.84
+1.24%
Alger Growth & Income A
JEPIX13.980.04
+0.29%
JPMorgan Equity Premium Income I
RYISX19.540.03
+0.15%
Guggenheim Long Short Equity C

CGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CGEN has been loosely correlated with NGNE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CGEN jumps, then NGNE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CGEN
1D Price
Change %
CGEN100%
+1.05%
NGNE - CGEN
51%
Loosely correlated
+0.30%
ORMP - CGEN
40%
Loosely correlated
+6.96%
AVRO - CGEN
39%
Loosely correlated
+2.11%
CYTK - CGEN
38%
Loosely correlated
+0.83%
AXON - CGEN
36%
Loosely correlated
+0.65%
More

NGNE and

Correlation & Price change

A.I.dvisor indicates that over the last year, NGNE has been loosely correlated with RNAZ. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if NGNE jumps, then RNAZ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NGNE
1D Price
Change %
NGNE100%
+0.30%
RNAZ - NGNE
56%
Loosely correlated
+4.74%
BRNS - NGNE
55%
Loosely correlated
+2.93%
CGEN - NGNE
51%
Loosely correlated
+1.05%
BPTSY - NGNE
38%
Loosely correlated
+3.41%
SNPX - NGNE
31%
Poorly correlated
+2.65%
More